Digital transformation is key to recovering from the pandemic and becoming competitive in the long term, but the strategy to close the digital gap and achieve digital readiness hinges on the empowerment of Filipinos. This is the main takeaway from Digital Readiness PH, a virtual town hall discussion led by…
Ocugen On Track to Submit Emergency Use Authorization Application to U S FDA for its COVID-19 Vaccine Candidate, COVAXIN™ streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
and Variant Neutralization Results In April 2021, Ocugen announced that its co-development partner, Bharat Biotech International Limited ( Bharat Biotech ), shared positive results from the second interim analysis of its Phase 3 clinical trial of COVAXIN showing 78% overall efficacy against COVID-19 disease, 100% efficacy against severe COVID-19 disease (including hospitalization), and 70% efficacy against asymptomatic COVID-19 infection, indicating the potential to significantly reduce virus transmission. COVAXIN has additionally demonstrated a remarkable safety profile with several million doses administered to date in India. Moreover, in-vitro studies conducted by the Indian Council of Medical Research-National Institute of Virology have provided data suggesting effectiveness in neutralizing the double mutant India variant, the U.K. variant, and the Brazil variant. Based on broad immunogenicity, Ocugen believes that COVAXIN has the potential to be effective against other emergi